Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Dec 1, 2025 · Filed Dec 1, 2025
Alkermes's R&D, Chief Medical Officer sold $117K of Alkermes shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$117,200
Shares × reported transaction price
34 days after results of Oct 28, 2025, 42 days before results of Jan 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.8% | +0.2% | −2.0% |
| 30 days | −2.5% | +0.2% | −2.7% |
| 90 days | +4.4% | +0.7% | +3.7% |
| 180 days | +45.9% | +11.3% | +34.6% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$112K of Alkermes plc
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.